We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.84 | -0.65% | 129.28 | 131.05 | 128.98 | 131.05 | 6,944,970 | 01:00:00 |
From May 2019 to May 2024
By Josh Beckerman
Merck & Co. has agreed to purchase biotechnology company Afferent Pharmaceuticals, whose lead drug candidate is being evaluated as a treatment for refractory, chronic cough and idiopathic pulmonary fibrosis with cough.
The deal will include an upfront payment of $500 million and milestones of up to $750 million.
San Mateo, Calif.-based Afferent focuses on targeting the P2X3 receptor for neurogenic conditions.
Last month, Afferent reported that its lead candidate, AF-219, significantly reduced cough frequency in the first cohort of a two cohort-Phase 2b study of chronic cough patients.
In July, Afferent said it completed a $55 million Series C financing led by Fidelity Management & Research Co.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
June 09, 2016 18:14 ET (22:14 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
